Highlights
- Ansell (ASX:ANN) reported FY26 sales of USD 2,140.2 million.
- Adjusted Earnings Per Share reached US 148.6 cents in FY26.
- Industrial and Healthcare segments both reported higher FY26 revenue.
- FY27 adjusted EPS guidance was US 158–170 cents.
Ansell Limited manufactures personal protective equipment for industrial and healthcare workplaces, including gloves and specialist protective products. During the November 16, 2026 session, Ansell (ASX:ANN) shares traded at AUD 46.64, up 0.71%. Its FY26 financial results showed higher sales and adjusted earnings, while the company outlined pricing, sourcing and productivity measures affecting its Business across international markets.
Industrial and Healthcare Protection
Ansell (ASX:ANN) reports two principal operating segments: Industrial and Healthcare. Industrial products include mechanical and chemical hand protection used in manufacturing, maintenance and specialist workplaces. Healthcare offerings include examination and surgical gloves and cleanroom products used in medical, scientific and controlled environments. Customer Demand varies by industry activity, workplace requirements and procurement arrangements.
The company operates internationally and reports financial results in United States dollars. This is distinct from its Australian-dollar share quotation. Its exposure to Manufacturing and global distribution means tariffs, sourcing costs and regional demand can affect sales and margins even when unit demand is relatively stable.
FY26 Sales and Operating Developments
Ansell recorded USD 2,140.2 million in FY26 sales, 6.8% above USD 2,003.3 million a year earlier. On an organic constant-currency basis, growth was 5.0%. Management also reported 5.7% adjusted sales growth after excluding temporary order-pattern effects. Such adjustments matter because pre-purchasing and shipment timing can temporarily alter comparisons between reporting periods.
Industrial segment sales were USD 947.3 million, up 5.4% as reported. The segment recorded adjusted earnings before interest and tax of USD 170.6 million. Healthcare sales were USD 1,192.9 million, up 8.0%, with adjusted segment EBIT of USD 170.7 million. Cleanroom sales increased 10.0% on the company’s adjusted basis, while surgical sales rose 6.4% on that measure.
Ansell (ASX:ANN) said pricing and sourcing actions had offset the effects of US tariffs and cost increases associated with disruptions in the Middle East during FY26. It also reported achieving its USD 50 million recurring pre-tax savings target under the Accelerated Productivity Investment Program, with enterprise-resource-planning upgrades next in the programme.
Financial Results and Industry Conditions
Adjusted EBIT increased 14.1% to USD 321.9 million, and its adjusted Margin expanded from 14.1% to 15.0%. Adjusted net profit reached USD 212.3 million, up 15.8%, while adjusted earnings per share increased 17.8% to US 148.6 cents. Statutory net profit was USD 208.6 million compared with USD 101.6 million. Adjusted measures exclude designated significant items and should be distinguished from statutory outcomes.
Operating cash flow, under Ansell’s defined measure, increased to USD 270.1 million from USD 105.4 million. Net Debt to adjusted EBITDA stood at 1.3 times at year-end. The company declared a full-year Dividend of US 68.1 cents per share and completed USD 118.4 million of its existing USD 200 million on-market share buyback programme in FY26.
Risks to Consider
Global protection equipment demand is sensitive to activity levels in healthcare, industry and scientific manufacturing. Material and freight costs, tariffs, currency movements and supply-chain interruptions can affect pricing and margins. Ansell (ASX:ANN) also faces execution considerations as it simplifies operations and introduces information-system changes. Management noted that the timing of further Tariff refunds remained uncertain. Temporary customer stocking before price increases can also distort the underlying pattern of quarterly orders.
What to Watch Next
For FY27, Ansell guided to adjusted EPS of US 158–170 cents, excluding buyback effects. It expected constant-currency sales growth through Volume and pricing, and forecast Capital Expenditure of USD 45–55 million. Investors can monitor segment sales, planned productivity improvements, ERP implementation costs and whether the assumptions supporting guidance remain applicable.
Key Insights
Ansell (ASX:ANN) reported higher FY26 sales, adjusted margins and operating cash flow. Results reflected contributions from both operating segments and the effects of pricing and cost measures. The FY27 outlook provides a measurable benchmark, while trade conditions, segment demand and implementation spending remain relevant to future performance.
_11_17_2026_11_03_15_426436.jpg)





Please wait processing your request...